-
How Contract Research Organizations (CROs) Can Optimize Their Workflows
Clinical trials are becoming more complex, more distributed, and more data-heavy. For contract research organizations (CROs), that means greater operational…
-
Customizing EDC Workflows for Specialty Pharma and Rare Disease Trials
Why Rare Disease and Specialty Pharma Trials Need Custom Workflows Rare disease and specialty pharma trials operate under very different…
-
The Role of EDC in Real-Time Decision-Making During Adaptive Trials
Adaptive clinical trials are built to respond to evidence as it emerges, allowing researchers to make changes midstream without compromising…
-
Why Scalable EDC Systems Matter in Global Pharmaceutical Trials
Clinical development rarely moves in a straight line. Programs expand across countries, add cohorts, refine eligibility criteria, and shift timelines…
-
How EDC Powers End-to-End Data Management in Pharma-Sponsored Clinical Trials
Electronic data capture, or EDC, continues to be a constant in modern clinical research studies. For pharmaceutical sponsors running complex,…
-
Crucial Data Solutions Names Dr. Leigh J. Mack Chief Medical Officer Amid Industry AI Shift
RENO, NV, UNITED STATES, July 17, 2025 — Crucial Data Solutions (CDS), provider of the industry’s only end-to-end eClinical platform…
-
How to Improve Patient Outcomes Using eSource Software in Clinical Trials
In the modern clinical research environment, improving patient outcomes is both a regulatory imperative and an ethical priority. The tools…
-
How EDC-Based SAE Reporting Reduces Time to Detection and Response in Clinical Trials
Serious adverse events (SAEs) are among the most critical data points collected during a clinical trial. The timeliness and accuracy…
-
Modern Post-Market Trials Will Be Driven by RWD – Is Your EDC Ready?
The Post-Market Shift: From Sites to Data Streams Phase IV trials used to mean tracking long-term outcomes by continuing to…
-
Smarter Clinical Trials for CNS and Pain: AI Analytics and Objective Measurement Tools
Clinical trials in pain and neurological research have historically faced steep hurdles: lengthy timelines, high costs, and subjective data endpoints…
